Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application.
作者： A ASCIERTO PAOLO , M MARINCOLA FRANCESCO , RIBAS ANTONI , None
关键词:
摘要: Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in overall survival in the treatment of advanced melanoma. These …
biomedcentral.com
springer.com
elsevier.com
paperity.org参考文章(23)
Andreas Hutloff, Anna M. Dittrich, Katja C. Beier, Barbara Eljaschewitsch, Regine Kraft, Ionnis Anagnostopoulos, Richard A. Kroczek, ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 Nature. ,vol. 397, pp. 263- 266 ,(1999) , 10.1038/16717
R. Lin, M. J. Yellin, I. Lowy, A. Safferman, K. Chin, R. Ibrahim, An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy Journal of Clinical Oncology. ,vol. 26, pp. 9063- 9063 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.9063
J. M. Kirkwood, P. Lorigan, P. Hersey, A. Hauschild, C. Robert, D. McDermott, M. A. Marshall, J. Gomez-Navarro, J. Q. Liang, C. A. Bulanhagui, Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma Clinical Cancer Research. ,vol. 16, pp. 1042- 1048 ,(2010) , 10.1158/1078-0432.CCR-09-2033
Geoffrey Y. Ku, Jianda Yuan, David B. Page, Sebastian E. A. Schroeder, Katherine S. Panageas, Richard D. Carvajal, Paul B. Chapman, Gary K. Schwartz, James P. Allison, Jedd D. Wolchok, Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival Cancer. ,vol. 116, pp. 1767- 1775 ,(2010) , 10.1002/CNCR.24951
C. I. Liakou, A. Kamat, D. N. Tang, H. Chen, J. Sun, P. Troncoso, C. Logothetis, P. Sharma, CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 14987- 14992 ,(2008) , 10.1073/PNAS.0806075105
Hiroto Inaba, Margherita Londero, Scott H. Maurer, Mihaela Onciu, Yubin Ge, Jeffrey W. Taub, Jeffrey E. Rubnitz, Susana C. Raimondi, Acute Megakaryoblastic Leukemia Without GATA1 Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome Journal of Clinical Oncology. ,vol. 29, pp. e230- e233 ,(2011) , 10.1200/JCO.2010.32.3634
E. Simeone, G. Gentilcore, A. Esposito, M. Curvietto, P. De Rosa, E. De Maio, M.P. Pistillo, P. Queirolo, N. Mozzillo, P.A. Ascierto, 9322 POSTER Immunological and Biological Changes and Their Correlation With Clinical Response and Survival During Ipilimumab in Metastatic Melanoma Compassionate Use Program European Journal of Cancer. ,vol. 47, ,(2011) , 10.1016/S0959-8049(11)72531-X
Evan M. Hersh, Steven J. O’Day, John Powderly, Khuda D. Khan, Anna C. Pavlick, Lee D. Cranmer, Wolfram E. Samlowski, Geoffrey M. Nichol, Michael J. Yellin, Jeffrey S. Weber, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investigational New Drugs. ,vol. 29, pp. 489- 498 ,(2011) , 10.1007/S10637-009-9376-8
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, Susan M. Domchek, Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells Clinical Cancer Research. ,vol. 16, pp. 3485- 3494 ,(2010) , 10.1158/1078-0432.CCR-10-0505
S Ahmad, M Lewis, P Corrie, M Iddawela, Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. Journal of Oncology Pharmacy Practice. ,vol. 18, pp. 287- 292 ,(2012) , 10.1177/1078155211411001